Y. Dean

发表

Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins

S. Kostense, W. Jiskoot, D. Weinbuch, 2013, Pharmaceutical Research.

Phase I, double‐blind, randomized, placebo‐controlled, dose‐escalation study of NI‐0401 (a fully human anti‐CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease†

P. Rutgeerts, D. Hommes, D. D. de Jong, 2010, Inflammatory bowel diseases.

Structural Decoding of the Netrin-1/UNC5 Interaction and its Therapeutical Implications in Cancers.

Trushar R. Patel, D. Neves, P. Mehlen, 2016, Cancer cell.

Short-Term Treatment With Anti-CD3 Antibody Reduces the Development and Progression of Atherosclerosis in Mice

F. Mach, S. Steffens, L. Chatenoud, 2006, Circulation.

Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments.

W. Reith, C. Gabay, C. Lamacchia, 2012, Arthritis and rheumatism.

Molecular and Cellular Properties of the Rat AA4 Antigen, a C-type Lectin-like Receptor with Structural Homology to Thrombomodulin*

P. Gasque, E. McGreal, H. Akatsu, 2000, The Journal of Biological Chemistry.

Endothelial cells, megakaryoblasts, platelets and alveolar epithelial cells express abundant levels of the mouse AA4 antigen, a C‐type lectin‐like receptor involved in homing activities and innate immune host defense

P. Gasque, E. McGreal, Y. Dean, 2001, European journal of immunology.

Complement components of the innate immune system in health and disease in the CNS.

P. Gasque, B. Morgan, E. McGreal, 2000, Immunopharmacology.

Pivotal Involvement of Fcγ Receptor IIA in the Neutralization of Lipopolysaccharide Signaling via a Potent Novel Anti-TLR4 Monoclonal Antibody 15C1*

J. Pugin, I. Dunn-Siegrist, G. Elson, 2007, Journal of Biological Chemistry.

A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.

Daniel Kramer, Claudia Berger, Cathelijne Kloks, 2015, Journal of immunological methods.

Characterization of a surrogate murine antibody to model anti-human CD3 therapies

W. Reith, L. Cons, Fabien Dépis, 2013, mAbs.

Roles of the complement system in human neurodegenerative disorders

P. Gasque, B. Morgan, J. Neal, 2002, Molecular Neurobiology.

Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins

S. Kostense, W. Jiskoot, D. Weinbuch, 2013, Pharmaceutical Research.

Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases.

Y. Dean, M. Kosco-Vilbois, F. Dépis, 2012, Swiss medical weekly.

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

P. Rutgeerts, D. Hommes, G. D'Haens, 2008 .